Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82,370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The burden and management competency of cardiomyopathies in China: a nationwide survey study.
Zhang Y, Liu M, Li P, Ma L, Yin L, Cui Y, Huang K, Li W, Xin H, Xiang M, Dai C, Chen M, Feng J, Zheng Z, Xu Y, Chen Y, Jiang X, Ma G, Yang P, Wang F, Li X, Jin W, Chen H, Hui R, Wang L, Xiao H, Liu L, Zou Y, Song L. Zhang Y, et al. Among authors: li w, li x, li p. Lancet Reg Health West Pac. 2024 Apr 11;46:101062. doi: 10.1016/j.lanwpc.2024.101062. eCollection 2024 May. Lancet Reg Health West Pac. 2024. PMID: 38623390 Free PMC article.
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.
Han X, Zhang M, Wang H, Zhang Q, Li W, Hao M, Gao Y, Jin J, Ren H, Tang Y, Hong X, Ke X, Su H, Gui L, Luo J, Xie L, Gai W, Shi Y. Han X, et al. Among authors: li w. Chin J Cancer Res. 2022 Dec 30;34(6):601-611. doi: 10.21147/j.issn.1000-9604.2022.06.08. Chin J Cancer Res. 2022. PMID: 36714342 Free PMC article.
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L, Zhang W, Fan N, Cao P, Cheng Y, Zhu L, Luo S, Zong H, Bai Y, Zhou J, Deng Y, Ba Y, Liu T, Aili M, Yin X, Gu K, Dai G, Ying J, Shi J, Gao Y, Li W, Yu G, Xie L, Gai W, Wang Y, Meng P, Shi Y. Yang L, et al. Among authors: li w. EBioMedicine. 2024 Feb;100:104966. doi: 10.1016/j.ebiom.2024.104966. Epub 2024 Jan 13. EBioMedicine. 2024. PMID: 38217945 Free PMC article. Clinical Trial.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J. Zhang Y, et al. Among authors: li f, li y, li w. Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343062 Clinical Trial.
82,370 results
You have reached the last available page of results. Please see the User Guide for more information.